<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253797</url>
  </required_header>
  <id_info>
    <org_study_id>1182.24</org_study_id>
    <nct_id>NCT02253797</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects</brief_title>
  <official_title>A Phase I Multiple Oral Dose Trial of Tipranavir 500 mg/Ritonavir 200 mg Dosed to Steady State Followed by Single-dose 14C-radiolabeled Tipranavir Co-administered With Tipranavir 500 mg/Ritonavir 200 mg to Characterize the Excretion Balance and Metabolite Profile of 14C-radiolabeled Tipranavir in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate the pharmacokinetics of Tipranavir and its metabolites including excretion
      and mass balance of parent compound and radioactivity at steady-state; to isolate, identify
      and quantify major metabolites of tipranavir in plasma, urine and feces
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radioactive levels of 14C-Tipranavir in plasma and blood</measure>
    <time_frame>-10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radioactive erythrocyte-plasma partition ratio</measure>
    <time_frame>-10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>-10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration</time_frame>
    <description>14C-radiolabeled Tipranavir + Tipranavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration 12 hours after dosing (Cp12h)</measure>
    <time_frame>-10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration</time_frame>
    <description>14C-radiolabeled Tipranavir + Tipranavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration time curve (AUC)</measure>
    <time_frame>-10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration</time_frame>
    <description>14C-radiolabeled Tipranavir + Tipranavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration (Tmax)</measure>
    <time_frame>-10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration</time_frame>
    <description>14C-radiolabeled Tipranavir + Tipranavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half life (t1/2)</measure>
    <time_frame>-10 minutes, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 hours after dose administration</time_frame>
    <description>14C-radiolabeled Tipranavir + Tipranavir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative amount of 14C- radioactivity in Urine and feces</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent excretion in urine and feces</measure>
    <time_frame>up to 15 days</time_frame>
    <description>relative to total radioactivity administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time needed to achieve steady-state as determined by tipranavir trough concentrations</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in laboratory parameters</measure>
    <time_frame>up to day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant changes in Electrocardiogram (ECG)</measure>
    <time_frame>up to day 6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TPV/r followed by 14C-radiolabeled TPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-Tipranavir</intervention_name>
    <arm_group_label>TPV/r followed by 14C-radiolabeled TPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>TPV/r followed by 14C-radiolabeled TPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>TPV/r followed by 14C-radiolabeled TPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy HIV-negative male subjects as determined by results of screening. Healthiness
             was determined by medical history, laboratory testing and 12-lead ECG

          2. Signed written informed consent in accordance with Good Clinical Practice (GCP)

          3. Age &gt;18 and &lt;=60 years

          4. Subjects within 20% of the normal height: weight range defined by the Metropolitan
             Life Insurance Company Tables

          5. Ability to swallow numerous large capsules

          6. Willingness to abstain from smoking, ingesting methylxanthine containing drinks or
             food (coffee, tea, cola, chocolate, etc.), or ingesting alcohol, St. John's Wort, milk
             thistle, garlic supplements, Seville oranges, and grapefruit or grapefruit juice for
             the duration of the study

        Exclusion Criteria:

          1. Any finding of the medical examination (including blood pressure, pulse rate, and ECG)
             deviating from normal and of clinical relevance

          2. History of clinically significant disease including metabolic, endocrinologic,
             immunological, hepatic, renal, gastrointestinal, respiratory, cardiovascular,
             psychiatric or neurological

          3. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator and/or the sponsor

          4. Subjects with a history of drug abuse or alcoholism

          5. Chronic or relevant acute (within 2 weeks of screening) infections

          6. Subjects who have taken prescription medications, over-the-counter drugs, or herbal
             preparations within 2 weeks of the start of the trial

          7. Participation in another trial with an investigational drug (in the 30 days prior to
             screening)

          8. Blood donation &gt;400 mL (within 1 month prior to treatment administration or during the
             trial)

          9. Any laboratory value that represents a Division of DAIDS (DAIDS) toxicity Grade &gt;1

         10. Positive urine drug screen, positive HIV antibody, positive Hepatitis C Ribonucleic
             acid (RNA), or positive Hepatitis B surface antigen

         11. History of any familial bleeding disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

